Speciality Medicines Limited

Speciality Medicines Limited, established on February 5, 2021, is a public limited company headquartered in Ahmedabad, Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U85300GJ2021PLC120022. As of March 31, 2023, Speciality Medicines Limited reported an annual revenue of approximately $2.8 million USD and a net profit of $264,620 USD. The company employs a dedicated team of 17 professionals committed to delivering high-quality pharmaceutical products. Speciality Medicines Limited specializes in the marketing and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, focusing on complex and chronic medical conditions. The company's product portfolio spans therapeutic areas such as oncology, immunology, neurology, and rare diseases.

Speciality Medicines Limited operates modern, temperature-controlled warehouses in multiple locations, including India and Africa, to ensure the safe storage and distribution of its pharmaceutical products. While specific details about manufacturing plant locations and capacities are not publicly disclosed, the company's infrastructure supports its extensive distribution network across more than 20 states in India and over 35 countries globally.

The leadership team at Speciality Medicines Limited comprises individuals with extensive experience in the pharmaceutical industry. Parthkumar Babulal Goyani serves as the Managing Director, overseeing the company's strategic direction and operations. Sumeet Babulal Goyani holds the position of Whole-Time Director, contributing to the company's growth and development. Chandresh Madhubhai Unagar is also a Director, playing a pivotal role in the company's management. Additionally, Kalpesh Bharatbhai Pipaliya was appointed as the Chief Financial Officer (CFO) on August 29, 2025, bringing valuable financial expertise to the organization.

Speciality Medicines Limited has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has been actively involved in obtaining necessary regulatory approvals and market access in these regions. In March 2026, Speciality Medicines Limited announced its Initial Public Offering (IPO), aiming to raise ₹29.14 crore (approximately $3.5 million USD) by offering 2,350,000 equity shares at a price band of ₹117-124 per share. The proceeds from the IPO are intended to support the establishment of a dedicated Research and Development (R&D) center, product registrations in international markets, and marketing and promotional activities, indicating the company's commitment to enhancing its global footprint.

Speciality Medicines Limited has strategically expanded its reach into emerging markets, including Africa, Latin America, and Southeast Asia. The company's focus on these regions is facilitated by its adherence to international quality standards, such as Good Manufacturing Practice (GMP) certifications, which enhance its credibility and facilitate market entry. By leveraging these certifications, Speciality Medicines Limited aims to establish a robust presence in these emerging markets, catering to the growing demand for specialty pharmaceutical products.

Speciality Medicines Limited's geographic strategy demonstrates a balanced approach, with a strong presence in both domestic and international markets. The company's export activities, as reported by TransData Nexus, include a total export value of $345,000 USD across 76 shipments, with a portfolio concentration of 99.4% in its top five products. This indicates a focused product strategy, primarily in the Advanced Oncology therapeutic category, which constitutes 86.5% of its exports. The company's expansion into emerging markets further diversifies its geographic footprint, mitigating concentration risks and positioning it for sustainable growth.

Speciality Medicines Limited has been proactive in engaging with the U.S. Food and Drug Administration (FDA) to ensure compliance with regulatory standards. The company has registered its manufacturing facilities with the FDA, facilitating the export of its pharmaceutical products to the United States. While specific details regarding approved Abbreviated New Drug Applications (ANDAs) and Drug Master File (DMF) filings are not publicly disclosed, the company's adherence to international quality standards, such as GMP certifications, underscores its commitment to meeting FDA requirements. The company's proactive approach to regulatory compliance enhances its credibility and facilitates market access in the U.S.

Speciality Medicines Limited has obtained Good Manufacturing Practice (GMP) certifications from the World Health Organization (WHO) and the European Union (EU), demonstrating its commitment to maintaining high-quality manufacturing standards. These certifications are crucial for the company's operations, as they enable access to international markets and ensure that its products meet the stringent quality requirements of global health authorities. The company's adherence to WHO and EU GMP standards reflects its dedication to delivering safe and effective pharmaceutical products worldwide.

In India, Speciality Medicines Limited operates under the regulatory oversight of the Central Drugs Standard Control Organisation (CDSCO). The company holds the necessary manufacturing licenses and approvals from state drug controllers, ensuring compliance with national pharmaceutical regulations. Additionally, Speciality Medicines Limited has obtained export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT), facilitating its export activities. These regulatory compliances underscore the company's commitment to maintaining high standards of quality and safety in its operations.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Speciality Medicines Limited by regulatory authorities. This absence of adverse regulatory actions suggests that the company maintains a strong compliance record and adheres to the regulatory standards set by authorities such as the FDA, WHO, and CDSCO. The company's proactive approach to regulatory compliance contributes to its reputation as a reliable and trustworthy pharmaceutical exporter.

Speciality Medicines Limited operates in a competitive pharmaceutical export market, facing competition from both domestic and international companies. Key competitors include AmerisourceBergen, Entero Healthcare, Keimed, Sandor Medicaids, and Mahaveer Medi Sales. The company's focus on specialty pharmaceutical products, particularly in therapeutic areas such as oncology, immunology, neurology, and rare diseases, differentiates it from competitors. By offering a diverse portfolio of high-cost oral and injectable medications, Speciality Medicines Limited aims to capture a significant share of the market for complex and chronic medical conditions.

Speciality Medicines Limited distinguishes itself through its commitment to quality, innovation, and customer-centric approach. The company's adherence to international quality standards, such as GMP certifications from WHO and the EU, ensures that its products meet stringent safety and efficacy criteria. Additionally, the company's focus on high-cost specialty pharmaceuticals for complex chronic conditions positions it as a provider of innovative solutions in therapeutic areas like oncology, immunology, neurology, and rare diseases. The establishment of a dedicated R&D center, as planned with the proceeds from the IPO, is expected to further enhance the company's capabilities in product development and innovation.

Speciality Medicines Limited's strategic direction focuses on expanding its presence in the specialty pharmaceuticals sector, with an emphasis on high-cost oral and injectable medications for complex and chronic medical conditions. The company's recent IPO, which opened on March 20, 2026, aims to raise ₹29.14 crore (approximately $3.5 million USD) to support the establishment of an R&D center, product registrations in international markets, and marketing initiatives. This strategic move underscores the company's commitment to innovation, market expansion, and enhancing its global footprint.

Speciality Medicines Limited has established a robust supply chain, sourcing pharmaceutical products from well-known Indian manufacturers. The company's adherence to Good Distribution Practice (GDP) certification ensures the safe and efficient distribution of its products. The company's export activities, as reported by TransData Nexus, include a total export value of $345,000 USD across 76 shipments, indicating a consistent and reliable export volume. The company's proactive approach to regulatory compliance and quality assurance further enhances its reliability as a supplier.

Importers should verify the following certifications to ensure the quality and compliance of Speciality Medicines Limited's products:

• FDA Registration: Confirm that the company's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA). This can be verified through the FDA's official website or by contacting the company directly.